全腹腔内化疗联合或不联合贝伐珠单抗用于新诊断、理想减瘤的苗勒管起源癌女性的系列II期试验最终报告
两项II期试验评估全腹腔内卡铂联合紫杉醇方案(A组不用贝伐珠单抗,B组加用贝伐珠单抗)治疗理想减瘤的上皮性卵巢癌。A组40例、B组41例,主要终点为安全性和耐受性。两组中位无进展生存期分别为23.5个月和25个月,中位总生存期分别为68个月和79.7个月,加用贝伐珠单抗后3级疲劳和3-4级腹泻发生率更高。
要点
- 全腹腔内卡铂联合紫杉醇方案在理想减瘤的上皮性卵巢癌中可耐受且安全。
- 加用贝伐珠单抗后3级疲劳发生率37% vs 33%,3-4级腹泻22% vs 8%。
- A组和B组中位无进展生存期分别为23.5个月和25个月,中位总生存期分别为68个月和79.7个月。
核心结论
- 每周腹腔内给予卡铂和紫杉醇可耐受且安全,在这两项试验中联合或不联合贝伐珠单抗活性相似。
研究设计与样本
- 两项II期试验:A组不用贝伐珠单抗,B组加用贝伐珠单抗,共治疗81例患者(A组40例,B组41例)。
- 方案为第1天卡铂AUC 6,第1、8、15天紫杉醇60 mg/m2,21天为一周期;B组从第2周期起每周期静脉给予贝伐珠单抗15 mg/kg。
- 第1周期静脉化疗,后续所有周期腹腔内化疗。
- A组主要终点为安全性和耐受性及病理完全缓解率,B组主要终点为安全性和耐受性及腹腔内化疗周期完成率。
主要发现
- A组和B组中位年龄分别为59岁(范围36-76岁)和55岁(范围19-69岁)。
- A组和B组分别有68%和85%的患者完成至少4个周期治疗。
- B组较A组3级疲劳发生率更高(37% vs 33%),3-4级腹泻发生率更高(22% vs 8%)。
- A组和B组中位无进展生存期分别为23.5个月(95%CI 16.2-35.3)和25个月(95%CI 16.4-42.7)。
- A组和B组中位总生存期分别为68个月(95%CI 49.5-未达到)和79.7个月(95%CI 59.0-79.7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B). METHODS: Both trials consisted of carboplatin AUC 6 day 1, and paclitaxel 60 mg/m2 on days 1,8, 15 of a 21-day cycle; in Trial B, patients received IV bevacizumab 15 mg/kg every cycle starting cycle 2. Chemotherapy was administered IV for cycle 1 and then IP for all subsequent cycles. Primary objectives included safety and tolerability, pathologic CR rate (Trial A), and the rate of completion of IP cycles of therapy (Trial B). Progression-free (PFS), overall survival (OS), and pharmacokinetic analysis were secondary endpoints. RESULTS: 81 patients were treated on both trials (n = 40 and 41 in trials A and B, respectively). Median age for trials A and B was 59 (range, 36-76) and 55 (range, 19-69) years, respectively. 68% and 85% of patients, respectively for A and B, completed at least 4 cycles of treatment in both trials. Treatment with bevacizumab resulted in higher rates of grade 3 fatigue (37 versus 33%) and grade 3-4 diarrhea (22 versus 8%). Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B. CONCLUSIONS: Weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity with and without concommittant bevacizumab in these 2 trials.
引用
- Krasner CN, Castro C, Penson RT, et al. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019. PMID: 30765148. doi:10.1016/j.ygyno.2019.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。